Adma Biologics reported $95.28M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Adma Biologics USD 95.28M 19.52M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 329.84M 729K Sep/2026
Omeros USD 85.5M 2.28M Jun/2025
Takeda JPY 2.6T 161B Sep/2026